Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Single-arm Phase II Trial of Adagrasib in Patients With KRASG12C-mutant NSCLC, Including the Elderly (≥70 Years) or Patients With Poor Performance Status

NCT05673187 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT05673187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05673187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Single-arm Phase II Trial of Adagrasib in Patients With KRASG12C-mutant NSCLC, Including the Elderly (≥70 Years) or Patients With Poor Performance Status
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 12, 2023
Completion date
December 31, 2026
Enrollment
68 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

kras p.g12c, nsclc stage iv